Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial.

Xenofon BaraliakosEffie PournaraLaure GossecPhillip J MeaseRoisin WhiteEamonn O'BrienBarbara SchulzHelena Marzo-OrtegaLaura C Coates

Published in: RMD open (2022)

Nail dystrophy was identified as a predictor of response to secukinumab in patients with PsA with axial manifestations in the MAXIMISE trial. These findings may be explained by the nail-entheseal concept as part of the axial phenotype in PsA .

Keyphrases

prostate cancer
phase iii
ankylosing spondylitis
study protocol
phase ii
clinical trial
radical prostatectomy
early onset
open label
rheumatoid arthritis
double blind